IVERMECTIN

Search structure
Trade Names:
Synonyms:
Status: Approved (1996)
Entry Type: Unknown
Molecule Category: Parent
ATC: D11AX22
UNII: 8883YP2R6D

Structure
InChI Key SPBDXSGPUHCETR-JFUDTMANSA-N
Smile CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O
InChI
InChI=1S/C48H74O14.C47H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38;1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3;11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b13-12+,27-15+,32-14+;12-11+,26-14+,31-13+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+;25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m00/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C95H146O28
Molecular Weight 1736.18
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
MODULATOR Glutamate-gated chloride channel modulator ISBN PubMed FDA Wikipedia
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- 6480 - - 18
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 1 Nuclear hormone receptor subfamily 1 group H Nuclear hormone receptor subfamily 1 group H member 4
- 260 - - 77
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 39
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 100-200 - - 34
Transporter Primary active transporter P-type ATPase Calcium ATPase
- 16900 - - -
Transporter Primary active transporter P-type ATPase Sodium potassium ATPase
- 6480 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Onchocerciasis 4 D009855 ClinicalTrials
Lice Infestations 4 D010373 ClinicalTrials
Strongyloidiasis 4 D013322 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Elephantiasis, Filarial 3 D004605 ClinicalTrials
Blepharitis 3 D001762 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Malaria 3 D008288 ClinicalTrials
Severe Dengue 2 D019595 ClinicalTrials
Dermatitis, Atopic 2 D003876 ClinicalTrials
Trichuriasis 2 D014257 ClinicalTrials
Acne Vulgaris 2 D000152 ClinicalTrials
Dengue 2 D003715 ClinicalTrials
Alcoholism 1 D000437 ClinicalTrials
Infections 1 D007239 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Skin and subcutaneous tissue disorders Pruritus 27.5
Immune system disorders Urticaria 22.7
Investigations Body temperature increased 22.6
Nervous system disorders Headache 18.0
Gastrointestinal disorders Diarrhoea 17.0
Gastrointestinal disorders Diarrhoea 16.0
Nervous system disorders Headache 15.0
Respiratory, thoracic and mediastinal disorders Cough 11.0
Investigations Body temperature increased 10.0
Cardiac disorders Dizziness 10.0
Ear and labyrinth disorders Vertigo 10.0
Musculoskeletal and connective tissue disorders Synovitis 9.3
Respiratory, thoracic and mediastinal disorders Cough 8.0
Gastrointestinal disorders Abdominal distension 7.0
Investigations Body temperature increased 7.0
Cardiac disorders Chest pain 7.0
Gastrointestinal disorders Nausea 6.0
Skin and subcutaneous tissue disorders Pruritus 6.0
Cardiac disorders Dizziness 5.0
Gastrointestinal disorders Nausea 5.0
Ear and labyrinth disorders Vertigo 5.0
Cardiac disorders Tachycardia 3.5
Cardiac disorders Oedema peripheral 3.2
Gastrointestinal disorders Diarrhoea 3.0
Blood and lymphatic system disorders Eosinophilia 3.0
Skin and subcutaneous tissue disorders Pruritus 3.0
Cardiac disorders Dizziness 2.8
Skin and subcutaneous tissue disorders Pruritus 2.8
Gastrointestinal disorders Diarrhoea 2.0
Gastrointestinal disorders Diarrhoea 1.8
Gastrointestinal disorders Nausea 1.8
General disorders and administration site conditions Face oedema 1.2
Nervous system disorders Orthostatic hypotension 1.1
Gastrointestinal disorders Abdominal discomfort 1.0
Gastrointestinal disorders Abdominal distension 1.0
Psychiatric disorders Apathy 1.0
Musculoskeletal and connective tissue disorders Arthralgia 1.0
General disorders and administration site conditions Decreased appetite 1.0
Skin and subcutaneous tissue disorders Dermatitis 1.0
Cardiac disorders Dizziness 1.0
Psychiatric disorders Flat affect 1.0
Nervous system disorders Headache 1.0
General disorders and administration site conditions Lethargy 1.0
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 1.0
Skin and subcutaneous tissue disorders Rash 1.0
Gastrointestinal disorders Abdominal pain 0.9
General disorders and administration site conditions Asthenia 0.9
Gastrointestinal disorders Constipation 0.9
General disorders and administration site conditions Decreased appetite 0.9
Skin and subcutaneous tissue disorders Dermatitis 0.9
General disorders and administration site conditions Fatigue 0.9
Gastrointestinal disorders Gastrointestinal pain 0.9
Skin and subcutaneous tissue disorders Rash 0.9
Nervous system disorders Somnolence 0.9
Nervous system disorders Tremor 0.9
Immune system disorders Urticaria 0.9
Ear and labyrinth disorders Vertigo 0.9
Gastrointestinal disorders Vomiting 0.9

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
19.04
General disorders and administration site conditions
17.41
Nervous system disorders
12.09
Injury, poisoning and procedural complications
10.25
Infections and infestations
4.59
Psychiatric disorders
4.5
Gastrointestinal disorders
4.34
Immune system disorders
3.63
Respiratory, thoracic and mediastinal disorders
3.44
Vascular disorders
2.98
Musculoskeletal and connective tissue disorders
2.67
Investigations
2.53
Eye disorders
2.43
Cardiac disorders
2.24
Metabolism and nutrition disorders
2.01

Cross References

Resources Reference
CAS NUMBER 70288-86-7
ChEMBL CHEMBL1200633
FDA SRS 8883YP2R6D
Guide to Pharmacology 2373
SureChEMBL SCHEMBL44294
CONTENTS